Oncoinvent ASA – Mandatory notification of trade

Oslo, 3 November 2025: Reference is made to the stock exchange announcement published by Oncoinvent ASA (the "**Company**") on 29 October 2025 regarding the completion of the merger between the Company and the former Oncoinvent ASA (reg. no. 995 764 458) ("**Oncoinvent**") (the "**Merger**").

In connection with completion of the Merger, the former shareholders of Oncoinvent, including certain primary insiders of the Company and their close associates, have today been allocated consideration shares in the Company. More information about the allocation of consideration shares is included in the Prospectus published on 28 October 2025.

Please see the attached forms for further details on the allocation of consideration shares in the Merger to the Company's primary insiders and their close associates.

For more information, please contact:

Øystein Soug, Chief Executive Officer
Email: soug@oncoinvent.com

About Oncoinvent ASA
Oncoinvent is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. The lead product candidate, Radspherin®, uses the alpha-emitting radionuclide radium-224, directly targeting micro-metastases post-surgery, harnessing the benefits of modern radiopharmaceuticals without the complexities of biological targeting. Oncoinvent is investigating the safety and efficacy of Radspherin® in a clinical development program in two indications. One Phase 1 trial and one Phase 1/2a trial have been completed and one randomized Phase 2 trial is currently ongoing in the US, UK and Europe. Early clinical efficacy data are highly encouraging, and no serious toxicity or safety concerns have been reported to date. The Oncoinvent team consists of approx. 40 employees and runs a state-of-the-art manufacturing facility to produce drug products for clinical trials in Nydalen, Oslo. Oncoinvent is listed on Euronext Oslo Børs.